Table S1. Baseline characteristics

	Controls	Liver disease
	1541	358
Male (%)	861 (55.9)	168 (46.9)
Age at cohort entry (mean [SD])	16.90 (6.23)	17.89 (5.30)
Index of Multiple Deprivation		
Least deprived (IMD 1)	323 (21.0)	70 (19.6)
IMD2	283 (18.4)	69 (19.3)
IMD3	271 (17.6)	73 (20.4)
IMD4	340 (22.1)	85 (23.7)
Most deprived (IMD5)	321 (20.9)	61 (17.0)
Presence of other conditions		
Asthma (%)	255 (16.5)	103 (28.8)
Epilepsy (%)	8 (0.5)	2 (0.6)
Diabetes (%)	30 (1.9)	74 (20.7)
Mental disorders		
Anxiety disorders (%)	211 (13.7)	85 (23.7)
Depression (%)	156 (10.1)	83 (23.2)
Self-harm (%)	75 (4.9)	23 (6.4)
Substance abuse (%)	273 (17.7)	175 (48.9)

Table S2. Cumulative burden of events for anxiety disorders, depression, substance abuse and non-fatal self-harm in young people with chronic liver disease versus controls. Cumulative burden is shown as mean number of events per 100 individuals.

Groups	Outcome	Years of follow-	Cumulative	Lower CI	Upper CI
Vith liver disease	Anxiety disorders	up	burden 6.87	4.00	9.73
/ith liver disease /ith liver disease	Anxiety disorders Anxiety disorders	2	12.61 18.39	5.72 10.34	19.50 26.44
ith liver disease	Anxiety disorders Anxiety disorders	4	18.39 22.52	13.32	31.73
ith liver disease	Anxiety disorders Anxiety disorders	5	29.45 36.99	21.81 27.50	37.08 46.48
ith liver disease	Anxiety disorders Anxiety disorders	7	44.25	35.90	52.60
ith liver disease	Anxiety disorders Anxiety disorders	8	56.03 66.29	42.85 50.72	69.21 81.86
ith liver disease	Anxiety disorders	10	80.47	66.38	94.56
ontrols	Anxiety disorders Anxiety disorders	2	2.22 6.20	3.07	3.07 9.33
ontrols	Anxiety disorders	3	9.08	6.74	11.43
ontrols	Anxiety disorders Anxiety disorders	4 5	10.79 14.84	8.18 10.17	13.41 19.50
ontrols	Anxiety disorders	6	17.93	13.80	22.06
ontrols	Anxiety disorders Anxiety disorders	7	20.76	17.01 21.20	24.50 27.58
ntrols	Anxiety disorders	9	26.92	23.81	30.02
ntrols (without asthma, diabetes or epilepsy)	Anxiety disorders Anxiety disorders	10	30.86 2.08	26.93 1.20	34.79 2.96
entrols (without asthma, diabetes or epilepsy)	Anxiety disorders Anxiety disorders	2	6.80	4.88	8.72
ontrols (without asthma, diabetes or epilepsy)	Anxiety disorders Anxiety disorders	3	9.93 11.47	7.78 9.40	12.09 13.53
ntrols (without asthma, diabetes or epilepsy)	Anxiety disorders Anxiety disorders	5	14.06	11.19	16.92
entrols (without asthma, diabetes or epilepsy)	Anxiety disorders	6	16.84	15.93	17.76
ontrols (without asthma, diabetes or epilepsy) ontrols (without asthma, diabetes or epilepsy)	Anxiety disorders Anxiety disorders	7 8	19.86 23.25	18.75 21.18	20.97 25.33
entrols (without asthma, diabetes or epilepsy)	Anxiety disorders	9	26.06	23.20	28.92
ntrols (without asthma, diabetes or epilepsy)	Anxiety disorders	10	29.82	26.79	32.86
th liver disease th liver disease	Depression Depression	2	5.10 10.21	2.83 7.10	7.37 13.32
th liver disease	Depression	3	16.51	11.93	21.10
th liver disease	Depression Depression	5	23.54 28.02	17.17 21.02	29.91 35.03
th liver disease	Depression	6	31.75	24.95	38.55
th liver disease	Depression Depression	7 8	36.98 42.75	27.85 35.50	46.12 50.00
th liver disease	Depression	9	48.12	41.29	54.94
th liver disease introls	Depression Depression	10	55.79 0.86	0.53	62.34 1.19
ntrols	Depression	2	1.72	0.99	2.45
ontrols ontrols	Depression Depression	3	2.52 3.46	1.46 2.60	3.59 4.32
ontrols	Depression	5	5.01	4.16	5.86
ontrols ontrols	Depression Depression	6 7	6.58 8.39	5.75 6.73	7.40 10.06
ntrols	Depression	8	10.38	8.34	12.41
ntrols	Depression Depression	9	11.91 14.44	9.88	13.95 17.03
ntrols (without asthma, diabetes or epilepsy)	Depression	1	0.98	0.57	1.38
ntrols (without asthma, diabetes or epilepsy) ntrols (without asthma, diabetes or epilepsy)	Depression Depression	2	1.95 2.60	1.14	2.76 3.34
entrols (without asthma, diabetes or epilepsy)	Depression	4	3.75	2.44	5.06
ontrols (without asthma, diabetes or epilepsy)	Depression	5	5.39	3.68	7.11
ontrols (without asthma, diabetes or epilepsy) ontrols (without asthma, diabetes or epilepsy)	Depression Depression	7	7.21 8.57	5.48 6.25	8.94 10.89
ontrols (without asthma, diabetes or epilepsy)	Depression	8	10.63	8.28	12.98
ontrols (without asthma, diabetes or epilepsy) ontrols (without asthma, diabetes or epilepsy)	Depression Depression	9	12.22 14.53	9.64	14.79 17.39
th liver disease	Self-harm	1	3.09	1.12	5.05
th liver disease	Self-harm	2	4.21	1.40	7.02
th liver disease th liver disease	Self-harm Self-harm	3	5.06 5.35	2.80 3.38	7.33 7.33
th liver disease	Self-harm	5	5.94	4.24	7.64
th liver disease th liver disease	Self-harm Self-harm	7	6.85 7.49	4.51	9.19
th liver disease	Self-harm	8	7.49	4.84	10.15
th liver disease th liver disease	Self-harm Self-harm	9	7.49 7.87	5.20	10.15 10.53
ontrols	Self-harm	1	0.20	0.07	0.33
entrols entrols	Self-harm Self-harm	3	0.85 1.17	0.59	1.11
ontrols	Self-harm	4	1.56	1.24	1.89
ntrols	Self-harm Self-harm	5	1.96 2.70	2.03	2.36 3.37
ontrols	Self-harm	7	2.90	2.30	3.51
ontrols	Self-harm Self-harm	8	3.25 3.60	2.64	3.86 4.28
ontrols	Self-harm	10	4.50	3.96	5.04
entrols (without asthma, diabetes or epilepsy) entrols (without asthma, diabetes or epilepsy)	Self-harm Self-harm	2	0.24 1.04	0.08	0.40 1.67
ntrols (without asthma, diabetes or epilepsy)	Self-harm	3	1.43	0.72	2.15
entrols (without asthma, diabetes or epilepsy) entrols (without asthma, diabetes or epilepsy)	Self-harm Self-harm	5	1.75 2.16	1.04	2.47 2.79
entrols (without asthma, diabetes or epilepsy)	Self-harm	6	2.89	2.01	3.77
entrols (without asthma, diabetes or epilepsy)	Self-harm	7	3.05	2.17	3.94
ontrols (without asthma, diabetes or epilepsy) ontrols (without asthma, diabetes or epilepsy)	Self-harm Self-harm	8	3.30 3.65	2.25 2.51	4.35 4.79
entrols (without asthma, diabetes or epilepsy)	Self-harm	10	4.64	3.57	5.72
th liver disease	Substance abuse Substance abuse	1 2	10.61 29.93	9.50 26.84	11.73 33.02
th liver disease	Substance abuse Substance abuse	3	50.82	47.07	54.58
th liver disease	Substance abuse Substance abuse	4 5	72.15 95.04	67.90 88.18	76.40 101.90
h liver disease	Substance abuse Substance abuse	6	95.04	109.30	101.90
h liver disease	Substance abuse	7	138.16	125.52	150.80
th liver disease	Substance abuse Substance abuse	8	159.86 184.59	137.65 160.82	182.08 208.35
th liver disease	Substance abuse	10	201.82	178.22	225.42
ntrols	Substance abuse Substance abuse	1 2	1.23 2.08	0.71 1.23	1.75 2.92
ontrols	Substance abuse	3	3.31	2.27	4.35
ntrols	Substance abuse Substance abuse	5	4.75 6.19	3.90 5.01	5.60 7.38
ntrols	Substance abuse Substance abuse	6	7.33	5.94	8.71
ntrols	Substance abuse Substance abuse	7	9.23 11.16	7.86 10.06	10.60 12.25
ontrois	Substance abuse Substance abuse	9	13.07	11.36	12.25
ontrols	Substance abuse	10	14.99	13.31	16.68
entrols (without asthma, diabetes or epilepsy) entrols (without asthma, diabetes or epilepsy)	Substance abuse Substance abuse	2	0.80 1.59	0.64 1.19	0.95 1.99
ontrols (without asthma, diabetes or epilepsy)	Substance abuse	3	2.87	1.91	3.82
ontrols (without asthma, diabetes or epilepsy) ontrols (without asthma, diabetes or epilepsy)	Substance abuse Substance abuse	5	3.98 5.03	3.27 4.15	4.70 5.90
,					_

Controls (without asthma, diabetes or epilepsy)

Substance abuse

Substance abuse

Substance abuse

Substance abuse

Substance abuse

6

7

8

9

10

6.24

8.14

9.99

11.88

13.94

5.44

7.61

8.91

10.62

11.96

7.04

8.67

11.07

13.13

15.92

Table S3. Logistic regression analysis for the risk of anxiety disorder, depression, substance abuse and non-fatal self-harm. Case (young people with chronic liver disease) and control groups were obtained via propensity score matching. Controls were matched by year of birth, Index of Multiple Deprivation and sex.

Outcome	Odds ratio	Lower CI	Upper CI	P value	Analysis	
Depression	2.59	1.91	3.50	< 0.001	Controls vs. cases	
Anxiety disorders	1.94	1.45	2.58	< 0.001	Controls vs. cases	
Self-harm	1.42	0.85	2.28	0.165	Controls vs. cases	
Substance abuse	4.44	3.46	5.71	< 0.001	Controls vs. cases	
Depression	2.79	2.03	3.81	< 0.001	Controls (without asthma, diabetes and epilepsy) vs. cases	
Anxiety disorders	2.26	1.67	3.05	< 0.001	Controls (without asthma, diabetes and epilepsy) vs. cases	
Self_harm	1.41	0.84	2.30	0.184	Controls (without asthma, diabetes and epilepsy) vs. cases	
Substance abuse	4.68	3.62	6.07	< 0.001	Controls (without asthma, diabetes and epilepsy) vs. cases	